Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

Halozyme Therapeutics, Inc. today announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with Halozyme's proprietary ENHANZE technology.

21 Jan 2016

MD Anderson and AbbVie join forces to design new immunotherapy cancer patients

The immunotherapy platform at The University of Texas MD Anderson Cancer Center and the global biopharmaceutical company AbbVie will join forces to find new ways to unleash the immune system's potential to fight cancer.

21 Jan 2016

Philogen launches Phase III pivotal trial in patients with Stage IIIB/C melanoma

Philogen S.p.A. today announced the launch of a pivotal trial in patients with Stage IIIB/C melanoma, following promising results obtained in a Phase II study with an innovative immunotherapeutic approach.

21 Jan 2016

Scientists solve atomic structure of ubiquitin ligase complex that plays key role in protein degradation

Scientists at Sanford Burnham Prebys Medical Discovery Institute have solved the atomic structure of a unique ubiquitin ligase complex. Ubiquitin is best known for its role in protein degradation, but more recently seen as important for cell signaling, DNA repair, anti-inflammatory, and immune responses.

21 Jan 2016

UM SOM study leads to FDA approval of Neulasta drug for treatment of radiation injury

As a result of research performed by scientists at the University of Maryland School of Medicine, the U.S. Food and Drug Administration has approved the use of a drug to treat the deleterious effects of radiation exposure following a nuclear incident. The drug, Neulasta, is one of a very small number that have been approved for the treatment of acute radiation injury.

21 Jan 2016

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

OncoGenex Pharmaceuticals, Inc. announced today that data from the Phase 2 Spruce trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit.

20 Jan 2016

NextSource Biotechnology announces FDA approval of Gleostine (lomustine) 5 mg capsules

NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.

20 Jan 2016

Scientists reveal why non-alcoholic steatohepatitis worsens in obese people

In results published on October 19, 2015 in the Journal of Lipid Research, a team of translational scientists at the Medical University of South Carolina report a new reason why non-alcoholic steatohepatitis (NASH) worsens in people who are obese.

20 Jan 2016

New Penn study examines differences in costs of end-of-life care among developed countries

Despite widespread perception, the United States does not provide the worst end-of-life care in the world. In the first international comparison of end-of-life care practices, researchers from the Perelman School of Medicine at the University of Pennsylvania and colleagues from seven countries found that the United States actually has the lowest proportion of deaths in the hospital and the lowest number of days in the hospital in the last six months of life among the those countries, according to a new study published today in JAMA.

20 Jan 2016

Diabetes drug fails to show any benefit against pancreatic cancer

A diabetes drug that showed promise in previous studies as an anti-cancer treatment failed to show any benefit in a UNC Lineberger Comprehensive Cancer Center-led study that used pancreatic cancer tissue samples to test sensitivity to the drug.

20 Jan 2016

PD-L1 inhibition well-tolerated, active in metastatic RCC

The programmed death-ligand 1 inhibitor atezolizumab has a favourable toxicity profile and shows anti-tumour activity in previously treated patients with metastatic renal cell carcinoma, according to phase Ia trial findings.

19 Jan 2016

TG4010 vaccine promising in advanced NSCLC

Addition of the TG4010 vaccine to first-line chemotherapy improves outcomes in patients with advanced non-small-cell lung cancer, show the results of a placebo controlled trial.

19 Jan 2016

WASF3 protein appears to be solid target for reducing cancer metastasis

A protein that is constantly expressed by cancer cells and quiescent in healthy ones appears to be a solid target for reducing cancer's ability to spread, scientists report.

19 Jan 2016

CASI Pharmaceuticals receives $10.3 million in strategic financing

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announces it has received approximately $10.3 million in a strategic financing previously announced on September 21, 2015.

19 Jan 2016

Combination of PARP inhibitors and c-MET may benefit breast cancer patients

Findings from a new study reveal that PARP inhibitors, an emerging class of drugs being studied in cancer clinical trials, may be enhanced by combining them with inhibitors targeting an oncogene known as c-MET which is overexpressed in many cancers.

19 Jan 2016

Omnicell's revolutionary medication automation cabinet system saves cost, increases efficiency

An 18-month trial in the trust which opened England’s first hospital dedicated to emergency care, Northumbria Specialist Emergency Care Hospital, has found that significant cost-savings and efficiencies can be made by installing a revolutionary medication automation cabinet system provided by Omnicell Ltd, a leading provider of medication adherence packaging and automated healthcare solutions.

19 Jan 2016

UM SOM selected to work with BARDA to develop radiologic and nuclear countermeasures

University of Maryland School of Medicine Department of Radiation Oncology Chair and Professor William F. Regine, MD, FACR, FACRO, and UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that researchers at the UM SOM have been selected as key contractors by the Biomedical Advanced Research and Development Authority, for its Radiation Nuclear Animal Model Development program.

18 Jan 2016

PK molecule could be a target for vascular complications linked to type 1 diabetes

In an article published ahead of print on November 24, 2015 in the journal Diabetes (available at http://dx.doi.org/10.2337/db15-0930), researchers from the Medical University of South Carolina, the American University of Beirut, and Case Western Reserve University report that a molecule called pre-kallikrein (PK) could be a target for the vascular complications associated with type 1 diabetes.

18 Jan 2016

New report highlights resourcing issues in services for patients with bowel cancer

A new report published today (12 January 2016), by the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and Bowel Cancer UK, highlights numerous areas of service provision that fall short of having the resources needed to provide optimum service and safety for bowel disease patients.

18 Jan 2016

Scientists identify origins of anaplastic large cell lymphoma

Anaplastic large cell lymphoma (ALCL) is a very aggressive cancer of the blood, which usually occurs as a tumour in lymph nodes, the skin, the lungs, the liver, and in soft tissue, and mainly affects children and young adults.

18 Jan 2016

Oncology News and Research

Further Reading

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

MD Anderson and AbbVie join forces to design new immunotherapy cancer patients

Philogen launches Phase III pivotal trial in patients with Stage IIIB/C melanoma

Scientists solve atomic structure of ubiquitin ligase complex that plays key role in protein degradation

UM SOM study leads to FDA approval of Neulasta drug for treatment of radiation injury

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

NextSource Biotechnology announces FDA approval of Gleostine (lomustine) 5 mg capsules

Scientists reveal why non-alcoholic steatohepatitis worsens in obese people

New Penn study examines differences in costs of end-of-life care among developed countries

Diabetes drug fails to show any benefit against pancreatic cancer

PD-L1 inhibition well-tolerated, active in metastatic RCC

TG4010 vaccine promising in advanced NSCLC

WASF3 protein appears to be solid target for reducing cancer metastasis

CASI Pharmaceuticals receives $10.3 million in strategic financing

Combination of PARP inhibitors and c-MET may benefit breast cancer patients

Omnicell's revolutionary medication automation cabinet system saves cost, increases efficiency

UM SOM selected to work with BARDA to develop radiologic and nuclear countermeasures

PK molecule could be a target for vascular complications linked to type 1 diabetes

New report highlights resourcing issues in services for patients with bowel cancer

Scientists identify origins of anaplastic large cell lymphoma

Your guide to microplate readers for cancer research eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News